TNF and inflammatory bowel disease: The International Organization for the Study of Inflammatory Bowel Disease and British Society of Gastroenterology stated that the benefits of vaccination are likely to outweigh these theoretical concerns, even in patients treated with antitumor necrosis factor (TNF) drugs, and that the risks of COVID-19 vaccination in patients with IBD are anticipated to be very low.